Formoterol und Budesonid IHP nur 80µg/4,5µg (R03AK07)

TENDER DESCRIPTION

Kaufmännische Krankenkasse – KKH (hereinafter “KKH”) pursues the objective of concluding discount agreements pursuant to § 130a(8) of SGB V with all suitable pharmaceutical companies for the active ingredient stated under BT-21 lot (ATC) and, if applicable, restrictively for certain dosage forms within the scope of a so-called “Open-House procedure”. Subject to uniform contract terms and a uniform access procedure, the conclusion of, or accession to, a discount agreement pursuant to § 130a(8) of SGB V for the above-mentioned active ingredient shall be offered to all suitable and interested pharmaceutical companies or associations of pharmaceutical companies. Interested pharmaceutical companies may request the participation documents and the contract from the contact address stated. The condition for concluding a contract is that the interested pharmaceutical company submits the requested participation documents fully completed and signed. A contract shall be concluded with each pharmaceutical company that meets the participation requirements. No exclusivity is granted. Accession and/or contract conclusion may be carried out at any time under the same conditions. Individual…

TENDER BRIEF

TENDER DOCUMENTS